Focusing on the establishment of Sino Biological‘s Center for Bioprocessing (C4B) in Houston, it highlights how the ...

The purification of proteins and antibodies is a critical process in biotechnology and pharmaceutical industries. Traditional methods often involve single-use materials, leading to high costs and ...

Nuclera extended its Series C with $12M, bringing total to $87M, to expand Protein Discovery with full-format antibody ...

As therapeutic antibodies evolve, the industry is moving away from a one-size-fits-all chromatography approach. With an increasing share of non-traditional monoclonal antibodies (mAbs)—including ...

Efficient purification of plasmids, proteins, and antibodies is critical for drug target identification, drug candidate development, and fundamental research. However, traditional column-based methods ...

Alfa Cytology offers specialized radiolabeling and antibody-radionuclide conjugate development to advance radiopharmaceutical ...

Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...

Antibody manufacturers should be encouraged to revisit older technologies as the industry moves towards continuous processing. That’s the view of Andrew Zydney, PhD, professor, chemical engineering, ...

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new research paper from its global research and development Center (R&D ...

Nuclera has announced a $12million extension to its Series C round which raised $75m in October 2024. The raise was led by ...